Table 4.
Socio-demographic and clinical factors associated with IPT non-completion among PLHIV started on IPT from January 2017 to June 2018 at ART centers in two selected districts of Karnataka, India
| Characteristics | Initiated on IPT, N |
Not Completing IPT, n (%)c |
Unadjusted RR (95% CI) | Adjusted RR (95% CI) |
|---|---|---|---|---|
| Total | 1073 | 203 (18.9) | ||
| Age in years | ||||
| Less than 15 | 40 | 6 (15.0) | 0.9 (0.4–1.9) | 0.5 (0.2–1.4) |
| 15–24 | 103 | 22 (21.4) | 1.2 (0.8–1.9) | 0.8 (0.5–1.4) |
| 25–34 | 289 | 66 (22.9) | 1.3 (1.0–1.8) | 1.0 (0.8–1.4) |
| 35–44 | 356 | 61 (17.1) | 1 | 1 |
| 45–54 | 190 | 33 (17.4) | 1.0 (0.7–1.5) | 1.1 (0.8–1.7) |
| 55–64 | 77 | 11 (14.3) | 0.8 (0.5–1.5) | 0.9 (0.5–1.5) |
| ≥65 | 18 | 4 (22.2) | 1.3 (0.5–3.1) | 1.1 (0.5–2.3) |
| Gender | ||||
| Male | 479 | 85 (17.8) | 1 | 1 |
| Female | 586 | 117 (20.0) | 1.1 (0.9–1.5) | 1.2 (0.9–1.6) |
| Others | 8 | 1 (12.5) | 0.7 (0.1–4.5) | 0.3 (0.1–1.6) |
| Educationa | ||||
| Illiterate | 393 | 64 (16.3) | 1 | 1 |
| Primary school | 354 | 78 (22.0) | 1.4 (1.0–1.8) | 1.1 (0.8–1.5) |
| Secondary school | 225 | 42 (18.7) | 1.1 (0.8–1.6) | 0.8 (0.6–1.2) |
| College and above | 95 | 19 (20.0) | 1.2 (0.8–1.9) | 0.8 (0.5–1.3) |
| Not recorded | 6 | 0 (0.0) | - | - |
| Occupation | ||||
| Employed | 779 | 133 (17.1) | 1 | 1 |
| Student | 52 | 10 (19.2) | 1.1 (0.6–2.0) | 0.9 (0.4–1.9) |
| Housewife | 196 | 42 (21.4) | 1.3 (0.9–1.7) | 1.0 (0.7–1.4) |
| Unemployed/retired | 15 | 5 (33.3) | 2.0 (0.9–4.1) | 1.7 (0.8–3.6) |
| Not recorded | 31 | 13 (41.9) | 2.5 (1.6–3.8) | 1.1 (0.7–1.8) |
| Marital statusa | ||||
| Married/live-in | 660 | 122 (18.5) | 1 | 1 |
| Unmarried | 236 | 49 (20.8) | 1.1 (0.8–1.5) | 1.1 (0.8–1.5) |
| Widow | 120 | 30 (25.0) | 1.4 (1.0–1.9) | 1.5 (1.0–2.3) |
| Divorced/separated | 56 | 2 (3.4) | 0.2 (0.1–0.8) | 0.3 (0.1–1.2) |
| Not recorded | 1 | 0 (0.0) | - | - |
| Socio-economic classb | ||||
| Class I | 22 | 8 (36.4) | 3.0 (1.6–5.5) | 1.2 (0.6–2.4) |
| Class II | 87 | 24 (27.6) | 2.2 (1.4–3.5) | 1.1 (0.7–1.7) |
| Class III | 188 | 43 (22.9) | 1.9 (1.3–2.7) | 1.0 (0.7–1.6) |
| Class IV | 345 | 52 (15.1) | 1.2 (0.8–1.8) | 0.8 (0.6–1.3) |
| Class V | 324 | 40 (12.4) | 1 | 1 |
| Not recorded | 107 | 36 (33.6) | 2.7 (1.8–4.0) | 1.1 (0.7–1.7) |
| ART centers | ||||
| ART center 1 | 124 | 6 (4.8) | 1 | 1 |
| ART center 2 | 141 | 14 (9.9) | 2.1 (0.8–5.2) | 2.6 (1.0–6.8) |
| ART center 3 | 44 | 2 (4.6) | 0.9 (0.2–4.5) | 0.6 (0.1–4.5) |
| ART center 4 | 161 | 14 (8.7) | 1.8 (0.7–4.5 | 1.8 (0.7–4.8) |
| ART center 5 | 113 | 8 (7.1) | 1.5 (0.5–4.1) | 1.6 (0.6–4.6) |
| ART center 6 | 328 | 129 (39.3) | 8.1 (3.7–18.0) | 8.2 (3.6–18.9)d |
| ART center 7 | 162 | 30 (18.5) | 3.8 (1.7–8.9) | 4.4 (1.8–10.7)d |
| Body mass index (kg/m2)$ | ||||
| Underweight (<18.5) | 435 | 88 (20.3) | 1 | 1 |
| Normal (18.5–22.99) | 421 | 79 (18.8) | 0.9 (0.7–1.2) | 0.9 (0.7–1.2) |
| Overweight (23.0–24.99) | 100 | 16 (16.0) | 0.8 (0.5–1.3) | 0.7 (0.5–1.2) |
| Obese (≥25.0) | 116 | 19 (16.4) | 0.8 (0.5–1.3) | 0.7 (0.5–1.2) |
| Not recorded | 1 | 1 (100.0) | - | - |
| CD4 cell count (cells/mm3) | ||||
| Less than 200 | 390 | 59 (15.1) | 1 | 1 |
| 200–349 | 215 | 43 (20.0) | 1.3 (0.9–1.9) | 1.3 (0.9–1.8) |
| 350–500 | 185 | 44 (23.8) | 1.6 (1.1–2.3) | 1.4 (1.0–2.0) |
| More than 500 | 276 | 54 (19.6) | 1.3 (0.9–1.8) | 1.3 (0.9–1.8) |
| Not recorded | 7 | 3 (42.9) | 2.8 (1.2–6.9) | 2.8 (1.0–7.5)d |
| WHO Clinical Staginga | ||||
| Stages I and II | 999 | 190 (19.0) | 1 | 1 |
| Stages III and IV | 73 | 13 (17.8) | 1.0 (0.6–1.6) | 1.3 (0.8–2.0) |
| Not recorded | 1 | 0 (0.0) | - | - |
| Functional statusa | ||||
| Working | 1012 | 188 (18.6) | 1 | 1 |
| Ambulatory | 38 | 7 (18.4) | 1.0 (0.5–2.0) | 1.0 (0.6–2.0) |
| Bedridden | 23 | 8 (34.8) | 1.9 (1.1–3.3) | 1.2 (0.6–1.8) |
aAs categorized and recorded in the ART register.
bAs per BG Prasad Classification.
$WHO Classification for Asian population.
cRow Percentage.
dp value <0.05.
Abbreviations: ART, antiretroviral therapy; CD4, cluster of differentiation 4; CI, confidence interval; IPT, isoniazid preventive therapy; PLHIV, people living with HIV; RR, relative risk; TLE, tenofovir lamivudine efavirenz; WHO, World Health Organization.